

New issue of Xintelling No. 1 2026

[Read Xintela´s newsletter in English here](#)

Contacts

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: evy@xintela.se

Medicon Village

223 81 Lund, Sweden

www.xintela.se

About Xintela

Xintela ([XINT](#)) is a publicly-traded clinical-stage biopharma company, that develops cutting edge medical products in stem cell therapy and targeted cancer therapy. Xintela's proprietary technology uses the stem cell marker integrin $\alpha 10\beta 1$ to select and quality-assure the stem cell product XSTEM®, which has shown safety and positive efficacy results in clinical study on knee osteoarthritis and has now completed clinical study on difficult-to-heal leg ulcers. Xintela's in-house GMP-facility manufactures XSTEM and generates revenues by providing process development and manufacturing of other cell therapies. Xintela's wholly owned subsidiary Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin $\alpha 10\beta 1$. TARG9, an Antibody-Drug Conjugate (ADC), and TARG10, a function blocking antibody, are in preclinical development for the treatment of aggressive, difficult to treat cancers including triple-negative breast cancer and brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm. Xintela's Certified Adviser is Tapper Partners AB.

Image Attachments

[Xintelling Feb 2026 EN](#)

Press Release
20 February 2026 15:40:00 CET



Attachments

[New issue of Xintelling No. 1 2026](#)